Summary & Overview
CPT 0489U: Unity Fetal Risk Screen, Cell‑free DNA Prenatal Genetic Screening
CPT code 0489U designates the Unity Fetal Risk Screen™, a proprietary prenatal test from BillionToOne Laboratory that uses cell-free DNA sequencing to identify paternally inherited pathogenic variants and assess fetal inheritance of maternal mutations for disorders such as cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies. As a PLA code, 0489U is unique to a single manufacturer's assay and is used when that specific test is performed. Nationally, PLA codes like 0489U are increasingly important as genomic diagnostics expand and payers evaluate coverage and coding policies for proprietary tests.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical purpose of the test, the typical service and site of service, and which major payers are considered. The publication summarizes reimbursement and coverage considerations for a proprietary fetal risk screen, highlights benchmarks and payer policy themes relevant to PLA codes, and situates the test within prenatal genetic screening practices. The content provides clinical context for ordering clinicians and billing professionals and outlines what to expect in payer engagement and coding use for this specific assay. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0489U is a Proprietary Laboratory Analyses (PLA) code that applies only to the Unity Fetal Risk Screen™ manufactured and performed by BillionToOne Laboratory, BillionToOne Inc. The test uses cell–free DNA sequencing to detect paternally inherited pathogenic variants and to determine whether the fetus has inherited a maternal mutation, producing a fetal risk score for conditions including cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies, and alpha thalassemia.
Service type: Noninvasive prenatal genetic screening using cell-free DNA sequencing
Typical site of service: Clinical laboratory or outpatient specimen collection site (blood draw) with results reported to ordering clinician
Clinical & Coding Specifications
Clinical Context
A 28-year-old pregnant patient at 10–22 weeks gestation presents for prenatal genetic screening. The obstetrician or genetic counselor reviews family history revealing that one parent is a known carrier of a pathogenic variant for cystic fibrosis (CF), spinal muscular atrophy (SMA), beta hemoglobinopathies (including sickle cell disease and beta-thalassemia), or alpha thalassemia. The clinician orders the Unity Fetal Risk Screen™ (0489U) from BillionToOne Laboratory to assess fetal risk using cell-free DNA sequencing. A peripheral maternal blood draw is performed in the outpatient clinic or prenatal laboratory (typical site of service: outpatient laboratory or physician office). The sample is sent to the manufacturer’s laboratory for proprietary analysis. Results report a fetal risk score indicating whether the fetus likely inherited the maternal mutation and whether paternally inherited pathogenic variants are present. Results are reviewed by the ordering clinician; follow-up may include targeted diagnostic testing (amniocentesis or chorionic villus sampling) if a high-risk result is reported. Common payors reviewing claims include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unmodified - standard procedure | When the test is billed without any modifier adjustments. |
| | Professional component | When a separate physician professional component (interpretation) is billed in addition to the technical laboratory component.